GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
Gilead Sciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Market Cap | $189.80B | $197.05M |
| Enterprise Value | $212.78B | $106.56M |
| PS Ratio | 6.23 | 3.93 |
| PB Ratio | 16.05 | 2.14 |
| P/FCF Ratio | 14.66 | 18.25 |
| P/OCF Ratio | 14.01 | 13.78 |
Enterprise value
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| EV / Sales | 6.99 | 2.69 |
| EV / FCF | 16.44 | 21.02 |
Income (trailing twelve months)
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Revenue | $30.46B | $57.94M |
| Gross Profit | $24.24B | $90.47M |
| Operating Income | -$2.50B | -$21.44M |
| Pretax Income | -$1.96B | -$14.45M |
| Net Income | -$3.24B | -$22.46M |
| EBITDA | -$2.50B | -$16.91M |
| EPS (Diluted) | -$2.67 | -$0.83 |
Margins
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Gross Margin | 79.6% | 52.3% |
| Operating Margin | -8.20% | -44.5% |
| Pretax Margin | -6.42% | -13.0% |
| Profit Margin | -10.6% | -39.2% |
| EBITDA Margin | -8.20% | -31.3% |
| FCF Margin | 42.5% | -8.85% |
Returns
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | -20.6% | -53.1% |
| Return on Assets (ROA) | -6.17% | -41.0% |
| Return on Invested Capital (ROIC) | -5.31% | -32.0% |
| Return on Capital Employed (ROCE) | -6.51% | -37.8% |
Growth
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.52% | 6.01% |
| Net Income Growth (YoY) | -151.3% | -37.7% |
| EPS Growth (YoY) | -153.5% | -29.2% |
| FCF Growth (YoY) | 38.1% | 2.34% |
| Revenue Growth (3Y CAGR) | 2.57% | 2.25% |
| Revenue Growth (5Y CAGR) | 3.58% | 6.42% |
| EPS Growth (3Y CAGR) | 23.0% | -0.17% |
| EPS Growth (5Y CAGR) | 132.4% | 3.77% |
Balance sheet
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.18B | $62.42M |
| Total Debt | $26.25B | $120.13M |
| Net Cash (Debt) | -$23.07B | $15.68M |
| Net Cash Per Share | -$18.60 | $0.65 |
| Equity (Book Value) | $11.83B | $48.79M |
| Book Value Per Share | $9.54 | $1.36 |
| Tangible Book Value | -$10.52B | $23.06M |
| Working Capital | $2.93B | $75.77M |
Financial position
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Current Ratio | 1.27 | 3.30 |
| Quick Ratio | 0.75 | 2.39 |
| Debt / Equity | 2.22 | 0.51 |
| Debt / FCF | 2.03 | 5.05 |
| Interest Coverage | -2.50 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Operating Cash Flow | $13.55B | -$12.35M |
| Capital Expenditures | -$609.00M | -$1.06M |
| Free Cash Flow | $12.94B | -$20.28M |
| FCF Per Share | $10.44 | -$0.41 |
Efficiency
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Asset Turnover | 0.58 | 0.38 |
| Inventory Turnover | 3.29 | 2.67 |
| Revenue Per Employee | $1.79M | $398.96K |
| Profits Per Employee | -$190.59K | -$732.08K |
| Employee Count | 17,000 | 73 |
Dividends and yields
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Earnings Yield | -1.71% | -21.2% |
| FCF Yield | 6.82% | -7.64% |
| Dividend Yield | 2.06% | 1.83% |
| Buyback Yield | 0.60% | -0.58% |
| Shareholder Yield | 2.66% | 0.00% |
| Dividend Per Share | $3.16 | $0.83 |
| Dividend Growth (YoY) | 2.60% | 2.37% |
| Years of Dividend Growth | 11 | 0 |
| FCF Payout Ratio | 31.4% | 51.6% |
Shares
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Shares Outstanding | 1,239,960,000 | 59,128,900 |
| Shares Change (YoY) | -0.87% | 11.1% |
| Shares Change (QoQ) | -0.08% | 0.54% |
| Float | 1,238,700,000 | 48,744,500 |
| Shares Held by Insiders | 0.10% | 11.8% |
| Shares Held by Institutions | 89.9% | 59.4% |
Taxes
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Income Tax | $1.29B | $91.50K |
Scores
| Measure | Gilead Sciences | Industry median |
|---|---|---|
| Altman Z-Score | 3.61 | 0.10 |
| Piotroski F-Score | 8 | 4 |
Calculated by StockData from Gilead Sciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.